About Primary Hypercholesterolemia
Primary hypercholesterolemia comprises a range of disorders in which LDL cholesterol blood levels are above normal (usually above 200mg/dl or 5mmol/l) due to a number of possible genetic mutations such as familial hypercholesterolemia, where patients inherit a gene that prevents them from metabolizing LDL cholesterol properly. These patients face a markedly increased risk of premature cardiovascular disease and CVD-related death. For more information about Cholestagel, please visit http://www.cholestagel.com
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,500 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.
With many established products and services helping patients in nearly
90 countries, Genzyme is a leader in the effort to develop and apply the
most advanced technologies in the life sciences. The company's products and
services are focused on rare inherited disorders, kidney disease,
orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's
commitment to innovation continues today with a substantial development
|SOURCE Genzyme Corp.|
Copyright©2007 PR Newswire.
All rights reserved